Dan Becker
Director/Board Member bij DAY ONE BIOPHARMACEUTICALS, INC.
Vermogen: 102 850 $ op 31-03-2024
Profiel
Dan Becker is currently the Director at DTx Pharma, Inc. He is also the Managing Director at Access Biotechnology (Venture Capital), the Director at DOT Therapeutics-2, Inc., the Independent Director at ACELYRIN, Inc., the Director at Hemab ApS, the Independent Director at Day One Biopharmaceuticals, Inc., the Director at Mariana Oncology, Inc., the Director at Matchpoint Therapeutics, Inc., and the Principal at Access Industries LLC.
In the past, Dr. Becker worked as the Independent Director at Principia Biopharma, Inc. from 2017 to 2020, the Independent Non-Executive Director at Pandion Therapeutics, Inc. from 2020 to 2021, the Principal at The Boston Consulting Group, Inc. from 2009 to 2015, and the Principal at New Leaf Venture Partners LLC from 2015 to 2019.
Dr. Becker holds a doctorate degree from the University of Michigan, a graduate degree from the University of Michigan Medical School, and an undergraduate degree from the University of Illinois At Urbana–Champaign.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 15-03-2024 | 5 000 ( 0.01% ) | 82 600 $ | 31-03-2024 | |
ACELYRIN, INC.
0.00% | 09-05-2023 | 3 000 ( 0.00% ) | 20 250 $ | 31-03-2024 |
Actieve functies van Dan Becker
| Bedrijven | Functie | Begin |
|---|---|---|
| DAY ONE BIOPHARMACEUTICALS, INC. | Director/Board Member | 01-12-2019 |
| ACELYRIN, INC. | Director/Board Member | 01-09-2022 |
Access Biotechnology (Venture Capital)
 Access Biotechnology (Venture Capital) Investment ManagersFinance Access Biotechnology (Access Biotechnology) is a venture capital subsidiary of Access Industries, Inc. The firm is headquartered in New York. | Private Equity Investor | 01-08-2019 |
DOT Therapeutics-2, Inc.
 DOT Therapeutics-2, Inc. Pharmaceuticals: MajorHealth Technology DOT Therapeutics-2, Inc. develops new therapies that change the outcome for people of all ages living with cancer. The company was founded by Julie Grant and Samuel Blackman and is headquartered in South San Francisco, CA. | Director/Board Member | - |
| Access Industries LLC | Corporate Officer/Principal | 01-08-2019 |
DTx Pharma, Inc.
 DTx Pharma, Inc. Pharmaceuticals: MajorHealth Technology DTx Pharma, Inc. engages in the provision of biotechnology solutions. It focuses on the utilization of fatty acids to enable the delivery of RNA therapeutics to tissues and organ systems beyond the liver. The company was founded by Arthur T. Suckow, John Grundy, and Adam Pavlicek in August 2017 and is headquartered in San Diego, CA. | Director/Board Member | - |
Mariana Oncology, Inc.
 Mariana Oncology, Inc. BiotechnologyHealth Technology Mariana Oncology, Inc., also known as Curie Therapeutics, is a radiopharmaceuticals company that specializes in developing safe and effective targeted radiopharmaceuticals for cancer treatment. The company is based in Woburn, MA and was founded by Simon Read, who has been the CEO since incorporation. The company's radiopharmaceuticals are designed to deliver alpha and beta-emitting radionuclide payloads to carefully selected biological targets. | Director/Board Member | - |
Matchpoint Therapeutics, Inc.
 Matchpoint Therapeutics, Inc. BiotechnologyHealth Technology Matchpoint Therapeutics, Inc. is a biotechnology company based in Cambridge, MA. The company aims to discover and develop precision covalent medicines to transform the treatment of immune diseases and other serious illnesses. Matchpoint's proprietary Advanced Covalent Exploration (ACE) platform integrates advanced chemoproteomics, machine learning, and covalent chemistry library evolution. The company was founded by Jianwei Che, Edward Chouchani, Tinghu Zhang, Nathanael S. Gray, and the CEO is G. Andre Turenne. | Director/Board Member | - |
Hemab ApS
 Hemab ApS BiotechnologyHealth Technology Hemab ApS develops antibodies for the treatment of rare bleeding disorders. The company is based in Copenhagen, Denmark. The Danish company was founded in 2019 by Johan Henrik Faber. Benny Sorensen has been the CEO of the company since 2020. | Director/Board Member | - |
Eerdere bekende functies van Dan Becker
| Bedrijven | Functie | Einde |
|---|---|---|
| ░░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░ ░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░ ░░░░ ░░░░░░░ ░░░░░░░░ ░░░ | ░░░░░░░ ░░░░░░ ░░░░░░░░ | ░░░░░░░░░░ |
| ░░░ ░░░░░░ ░░░░░░░░░░ ░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Opleiding van Dan Becker
| University of Michigan | Doctorate Degree |
| University of Michigan Medical School | Graduate Degree |
| University of Illinois At Urbana–Champaign | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| ACELYRIN, INC. | Health Technology |
| DAY ONE BIOPHARMACEUTICALS, INC. | Health Technology |
| Bedrijven in privébezit | 11 |
|---|---|
Principia Biopharma, Inc.
 Principia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Principia Biopharma, Inc. is a biopharmaceutical company, which engages in designing and developing oral therapies to patients with significant unmet medical needs in immunology and oncology. It operates through Tailored Covalency platform, which enables to develop small molecule inhibitors of enzymes and receptor ligands with potencies and selectivities that rival those of injectable biologics, yet maintain the convenience of a pill. Its product pipeline includes PRN1008, PRN2246, PRN1371, and immunoproteasome inhibitor. The company was founded by Jack Taunton and Richard A. Miller on October 6, 2008 and is headquartered in South San Francisco, CA. | Health Technology |
| Access Industries LLC | |
The Boston Consulting Group, Inc.
 The Boston Consulting Group, Inc. Miscellaneous Commercial ServicesCommercial Services The Boston Consulting Group, Inc. engages in the provision of management consulting services. It specializes in automotive and mobility; biopharmaceuticals; consumer products; education; oil and gas; power and utilities; engineered products and infrastructure; financial institutions; and health care payers, providers, and services. It offers big data and advanced analytics; change management; client learning and enablement; and corporate development and financial services. The company was founded by Bruce Doolin Henderson in 1963 and is headquartered in Boston, MA. | Commercial Services |
New Leaf Venture Partners LLC
 New Leaf Venture Partners LLC Investment ManagersFinance New Leaf Venture Partners LLC (New Leaf Ventures) is an independent Venture Capital firm founded by Jeani Delagardelle, Philippe Chambon, Vijay Lathi, Ron Hunt, James Niedel, and Kathy LaPorte. The firm is headquartered in New York. It spun out from Sprout Group. | Finance |
DTx Pharma, Inc.
DTx Pharma, Inc. Pharmaceuticals: MajorHealth Technology DTx Pharma, Inc. engages in the provision of biotechnology solutions. It focuses on the utilization of fatty acids to enable the delivery of RNA therapeutics to tissues and organ systems beyond the liver. The company was founded by Arthur T. Suckow, John Grundy, and Adam Pavlicek in August 2017 and is headquartered in San Diego, CA. | Health Technology |
Access Biotechnology (Venture Capital)
Access Biotechnology (Venture Capital) Investment ManagersFinance Access Biotechnology (Access Biotechnology) is a venture capital subsidiary of Access Industries, Inc. The firm is headquartered in New York. | Finance |
Pandion Therapeutics, Inc.
 Pandion Therapeutics, Inc. BiotechnologyHealth Technology Pandion Therapeutics, Inc. is a clinical stage biopharmaceutical company. It develops Therapeutic Autoimmune reguLatOry proteiN (TALON) drug design and discovery platform, which employ a modular approach to create a pipeline of product candidates using immunomodulatory effector modules that act at known control nodes within the immune network. The company was founded by Dr. Joanne Viney on September 19, 2016 and is headquartered in Watertown, MA. | Health Technology |
DOT Therapeutics-2, Inc.
DOT Therapeutics-2, Inc. Pharmaceuticals: MajorHealth Technology DOT Therapeutics-2, Inc. develops new therapies that change the outcome for people of all ages living with cancer. The company was founded by Julie Grant and Samuel Blackman and is headquartered in South San Francisco, CA. | Health Technology |
Hemab ApS
Hemab ApS BiotechnologyHealth Technology Hemab ApS develops antibodies for the treatment of rare bleeding disorders. The company is based in Copenhagen, Denmark. The Danish company was founded in 2019 by Johan Henrik Faber. Benny Sorensen has been the CEO of the company since 2020. | Health Technology |
Mariana Oncology, Inc.
Mariana Oncology, Inc. BiotechnologyHealth Technology Mariana Oncology, Inc., also known as Curie Therapeutics, is a radiopharmaceuticals company that specializes in developing safe and effective targeted radiopharmaceuticals for cancer treatment. The company is based in Woburn, MA and was founded by Simon Read, who has been the CEO since incorporation. The company's radiopharmaceuticals are designed to deliver alpha and beta-emitting radionuclide payloads to carefully selected biological targets. | Health Technology |
Matchpoint Therapeutics, Inc.
Matchpoint Therapeutics, Inc. BiotechnologyHealth Technology Matchpoint Therapeutics, Inc. is a biotechnology company based in Cambridge, MA. The company aims to discover and develop precision covalent medicines to transform the treatment of immune diseases and other serious illnesses. Matchpoint's proprietary Advanced Covalent Exploration (ACE) platform integrates advanced chemoproteomics, machine learning, and covalent chemistry library evolution. The company was founded by Jianwei Che, Edward Chouchani, Tinghu Zhang, Nathanael S. Gray, and the CEO is G. Andre Turenne. | Health Technology |
